Abstract
Aprotinin is associated with an impressive reduction in postoperative blood loss after cardiac surgery [1]. The risk of transmission of infection with homologous blood transfusion has led to the call for the use of haemostatic agents, such as aprotinin, routinely during cardiopulmonary bypass [2]. There is concern however, that the haemostatic effect of the drug may reflect its thrombogenic potential and therefore, preclude its routine use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bildstrup BP, Royston D, Sapsford RN, Taylor KM (1989) Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364–373
Ferraris VA, Gildengorin V(1989) Predictors of excessive blood use after coronary artery bypass grafting. J Throac Cardiovasc 98: 492–497
Gorog P, Kovacs IB (1990) Modelling coronary thrombosis from non-anticoagulated human blood in-vitro. Haematologic Pathology 4(1): 43–52.
Kovacs IB, Hutton RA, Kernoff PBA (1989) Haemostatic evaluation in bleeding disorders from native blood. Clinical experience with the Haemostatometer. Am J Clin Pathol 91: 271–179
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ratnatunga, C.P., Gorog, P., Kovacs, I.B., Ress, G.M. (1991). The Effect of Aprotinin on Platelet Function and Coagulation In Vitro. In: Friedel, N., Hetzer, R., Royston, D. (eds) Blood Use in Cardiac Surgery. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-662-06119-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-06119-0_6
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-662-06121-3
Online ISBN: 978-3-662-06119-0
eBook Packages: Springer Book Archive